Literature DB >> 22749839

Human papillomavirus vaccine knowledge and hypothetical acceptance among women in Appalachia Ohio.

Mack T Ruffin1, Erinn M Hade, Melissa R Gorsline, Cecilia R DeGraffinreid, Mira L Katz, Sarah C Kobrin, Electra D Paskett.   

Abstract

OBJECTIVE: To assess hypothetical acceptance of the human papillomavirus (HPV) vaccine for themselves and a daughter age 9-12 years among Appalachia Ohio women.
METHODS: Women with an abnormal Pap smear and randomly selected women with a normal Pap smear from 17 clinics completed an interview in 2006-2008.
RESULTS: From 1131 original study participants, 807 (71%) completed a survey about the HPV vaccine for their daughters and themselves. Nearly half, 380 (47%), of the participants had heard of a vaccine to prevent cancer, and 362 (95%) of respondents had heard of HPV. The participants were then told that the FDA had approved a vaccine to prevent HPV. Only 379 (38%) participants identified girls ages 9-12 years as a group who should get the vaccine. After being given the official HPV vaccine recommendation statement, 252 (31%) wanted the vaccine; 198 (25%) were "not sure"; and 353 (44%) did not want the vaccine for themselves. With respect to giving the HPV vaccine to a daughter ages 9-12 years, participants responded "yes" 445 (55%); "not sure" 163 (20%); or "no" 185 (23%). Numerous reasons were provided supporting and opposing vaccine acceptance for themselves and for a daughter. Their physician's recommendation for the HPV vaccine increased vaccine acceptance to 86% for themselves and 90% for a daughter.
CONCLUSION: Knowledge, acceptance, and barriers about the HPV vaccine vary among women living in Appalachia Ohio. Physician recommendation is a key facilitator for vaccine diffusion in this region.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22749839      PMCID: PMC3886268          DOI: 10.1016/j.vaccine.2012.06.034

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  40 in total

1.  FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP).

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2010-05-28       Impact factor: 17.586

2.  Human papillomavirus vaccination series initiation and completion, 2008-2009.

Authors:  Christina G Dorell; David Yankey; Tammy A Santibanez; Lauri E Markowitz
Journal:  Pediatrics       Date:  2011-10-17       Impact factor: 7.124

3.  Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males.

Authors:  Anna R Giuliano; Joel M Palefsky; Stephen Goldstone; Edson D Moreira; Mary E Penny; Carlos Aranda; Eftyhia Vardas; Harald Moi; Heiko Jessen; Richard Hillman; Yen-Hwa Chang; Daron Ferris; Danielle Rouleau; Janine Bryan; J Brooke Marshall; Scott Vuocolo; Eliav Barr; David Radley; Richard M Haupt; Dalya Guris
Journal:  N Engl J Med       Date:  2011-02-03       Impact factor: 91.245

4.  Most parents do not think receiving human papillomavirus vaccine would encourage sexual activity in their children.

Authors:  Daron G Ferris; Lee Cromwell; Jennifer L Waller; Leslie Horn
Journal:  J Low Genit Tract Dis       Date:  2010-07       Impact factor: 1.925

5.  The association between cervical abnormalities and attitudes toward cervical cancer prevention.

Authors:  Talya Salz; Sami L Gottlieb; Jennifer S Smith; Noel T Brewer
Journal:  J Womens Health (Larchmt)       Date:  2010-09-16       Impact factor: 2.681

6.  Breast and cervical carcinoma mortality among women in the Appalachian region of the U.S., 1976-1996.

Authors:  H I Hall; J D Rogers; H K Weir; D S Miller; R J Uhler
Journal:  Cancer       Date:  2000-10-01       Impact factor: 6.860

7.  Parental decision making about the HPV vaccine.

Authors:  Jennifer D Allen; Megan K D Othus; Rachel C Shelton; Yi Li; Nancy Norman; Laura Tom; Marcela G del Carmen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-09       Impact factor: 4.254

Review 8.  The 2001 Bethesda System: terminology for reporting results of cervical cytology.

Authors:  Diane Solomon; Diane Davey; Robert Kurman; Ann Moriarty; Dennis O'Connor; Marianne Prey; Stephen Raab; Mark Sherman; David Wilbur; Thomas Wright; Nancy Young
Journal:  JAMA       Date:  2002-04-24       Impact factor: 56.272

9.  The Carolina HPV immunization attitudes and beliefs scale (CHIAS): scale development and associations with intentions to vaccinate.

Authors:  Annie-Laurie McRee; Noel T Brewer; Paul L Reiter; Sami L Gottlieb; Jennifer S Smith
Journal:  Sex Transm Dis       Date:  2010-04       Impact factor: 2.830

10.  Measuring cervical cancer risk: development and validation of the CARE Risky Sexual Behavior Index.

Authors:  Paul L Reiter; Mira L Katz; Amy K Ferketich; Mack T Ruffin; Electra D Paskett
Journal:  Cancer Causes Control       Date:  2009-12       Impact factor: 2.506

View more
  4 in total

1.  Human Papillomavirus Vaccine Uptake, Knowledge, and Acceptance for Youth: A Systematic Review of Appalachia.

Authors:  Chelsea Ryan; Kathryn L Duvall; Emily C Weyant; Kiana R Johnson; David Wood
Journal:  J Community Health       Date:  2018-06

2.  Correlates of HPV knowledge among low-income minority mothers with a child 9-17 years of age.

Authors:  S L Davlin; A B Berenson; M Rahman
Journal:  J Pediatr Adolesc Gynecol       Date:  2014-11-06       Impact factor: 1.814

3.  Results of a Multilevel Intervention Trial to Increase Human Papillomavirus (HPV) Vaccine Uptake among Adolescent Girls.

Authors:  Electra D Paskett; Jessica L Krok-Schoen; Michael L Pennell; Cathy M Tatum; Paul L Reiter; Juan Peng; Brittany M Bernardo; Rory C Weier; Morgan S Richardson; Mira L Katz
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-04       Impact factor: 4.254

4.  HPV prevalence among women from Appalachia: results from the CARE project.

Authors:  Paul L Reiter; Mira L Katz; Mack T Ruffin; Erinn M Hade; Cecilia R DeGraffenreid; Divya A Patel; Electra D Paskett; Elizabeth R Unger
Journal:  PLoS One       Date:  2013-08-30       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.